Complement 3 Glomerulopathy (C3G) Epidemiology Forecast Report 2017-2030 - ResearchAndMarkets.com

The "Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast to 2030 delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Complement 3 Glomerulopathy (C3G) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G), Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) and Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Complement 3 Glomerulopathy (C3G) Detailed Epidemiology Segmentation

• The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the seven major markets was found to be 8,175 in 2017.
• The diagnosed prevalent cases of Complement 3 Glomerulopathy (C3G), in the United States, were found to be 3,967 in 2017.
• It was found that in the United States, the number of cases of DDD and C3GN was 1,349 and 2,619, respectively, in 2017.
• Age-specific data for C3G suggests that in the United States the highest and the lowest number of cases of DDD were found in the age group of 18-50 with 830 cases and age-group >50 with 243 cases, respectively, in 2017, while the highest and the lowest number of cases of C3GN were found in the age group of 18-50 with 1,705 cases and age-group & less Than; 18 with 440 cases, respectively, in 2017.
• In the EU5 countries, the diagnosed prevalence of Complement 3 Glomerulopathy (C3G) was found to be maximum in Germany with 820 cases, followed by the France with 685 cases in 2017. While, the least number of cases were found in Spain, with 496 cases in 2017.
• In Japan, the diagnosed prevalence of Complement 3 Glomerulopathy (C3G) was found to be 912 in 2017.

Scope of the Report

• The report covers the descriptive overview of Complement 3 Glomerulopathy (C3G), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Complement 3 Glomerulopathy (C3G).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) and Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G).

Report Highlights

• Eleven Year Forecast of Complement 3 Glomerulopathy (C3G)
• 7MM Coverage
• Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)
• As per the analysis, Complement 3 Glomerulopathy (C3G) can be divided into two types, namely, Dense Deposit Disease (DDD) and C3 glomerulonephritis (C3GN).
• The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G), wherein various age groups have been considered, such as less Than; 18, 18-50 and >50. It has been found that the diagnosed prevalence of both DDD and C3GN has been found maximum in the 18-50 age group.
• Expected Launch of potential therapies, Danicopan (Alexion Pharmaceuticals), Narsoplimab (Omeros Corporation), Pegcetacoplan (Apellis Pharmaceuticals) and LNP023 (Novartis Pharmaceuticals), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Complement 3 Glomerulopathy (C3G).
• The current treatment of Complement 3 Glomerulopathy (C3G) is mainly dominated by the use of off-label therapies, which includes Immunosuppressant, Steroids, Renin-angiotensin-aldosterone system Inhibitors (RAAS) and Other Supportive Therapies (also including Antibody regimens: Eculizumab and Rituximab).

Key Topics Covered:

1 Key Insights

2 C3G Overview at a Glance

3 Executive Summary of Complement 3 Glomerulopathy (C3G)

4 Complement 3 Glomerulopathy (C3G): Disease Background and Overview

4.1 Types

4.1.1 Dense Deposit Disease (DDD)

4.1.2 C3 glomerulonephritis (C3GN)

4.2 Familiar forms of C3G

4.2.1 CFHR5 nephropathy

4.2.2 Other familiar forms of C3G

4.3 Causes and Risk Factors

4.3.1 Genetic or Hereditary Risk Factors

4.3.2 Acquired Risk Factors

4.4 Clinical Presentation

4.5 Histological Patterns

4.6 Symptoms

4.7 Pathophysiology

4.8 Pathogenesis

4.9 Diagnosis

4.10 Challenges in Diagnosis

4.10.1 Immune complex glomerulonephritis

4.10.2 Postinfectious glomerulonephritis

4.10.3 Predictors of progression

4.11 Differential Diagnosis

4.12 Prognosis

5 Algorithm for Diagnosis and Management of C3G

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy

7 Country-wise Epidemiology of Complement 3 Glomerulopathy

7.1 United States

7.1.1 Assumptions and Rationale

7.1.2 Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the US

7.1.3 Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the US

7.1.4 Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy in the US

7.2 EU5 Countries

7.2.1 Assumptions and Rationale

7.3 Germany

7.4 France

7.5 Italy

7.6 Spain

7.7 United Kingdom

7.8 Japan

7.8.1 Assumptions and Rationale

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/dldg36

View source version on businesswire.com: https://www.businesswire.com/news/home/20201002005381/en/